Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Multi-center randomized open l...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Bibliographic Details
Main Authors: Jaap J. Zwaginga, Bronno van der Holt, Peter A. te Boekhorst, Bart J. Biemond, Mark-David Levin, René van der Griend, Anneke Brand, Sonja Zweegman, Hans F.M. Pruijt, Vera M.J. Novotny, Art Vreugdenhil, Marco R. de Groot, Okke de Weerdt, Elisabeth C.M. van Pampus, Tanja M. van Maanen-Lamme, Shulamiet Wittebol, Martin R. Schipperus, Matthijs H. Silbermann, Peter C. Huijgens, Marleen Luten, Rene Hollestein, Jan A.C. Brakenhoff, Jolanda G. Schrama, Fransje A.A. Valster, Gerjo A. Velders, Harry R. Koene
Format: Article
Language:English
Published: Ferrata Storti Foundation 2015-03-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/7325
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://haematologica.org/article/view/7325

Similar Items

  • Comment to: Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403
    by: Ellen van der Spek, et al.
    Published: (2008-07-01)
  • Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival
    by: Henk M. Lokhorst, et al.
    Published: (2015-12-01)
  • P1630: WEARABLES IN TRANSFUSION MEDICINE: CHALLENGES AND FUTURE PERSPECTIVE
    by: R. Tonino, et al.
    Published: (2022-06-01)
  • Hemoglobin modulation affects physiology and patient reported outcomes in anemic and non-anemic subjects: An umbrella review
    by: R. P. B. Tonino, et al.
    Published: (2023-02-01)
  • Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
    by: Michael. S. van der Veer, et al.
    Published: (2011-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs